Amneal Pharmaceuticals AMRX Revenue Breakdown

NASDAQ AMRX
$21.23 -0.15 (-0.70%)
At close: Nov 16, 2026 · 4:00 PM EST
Annual revenue breakdowns for Amneal Pharmaceuticals, fiscal 2016 to 2025, as reported in its filings.
Annual history

Amneal Pharmaceuticals Revenue by Segment

Years FY 2016–2025
Lines 3
FY 2025 Total $3.02B

Affordable Medicines was Amneal Pharmaceuticals’s largest segment in fiscal 2025, bringing in $1.75B of $3.02B (58%).

Amneal Pharmaceuticals revenue by segment, fiscal 2016 to 2025
Segment FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Affordable Medicines $1.43B $1.47B $1.69B $1.75B
Avkare $406.11M $531.75M $662.95M $744.73M
Specialty $374.12M $390.46M $445.75M $528.51M
Total $2.21B $2.39B $2.79B $3.02B
Totals include 1 discontinued line from earlier reporting.

Amneal Pharmaceuticals revenue by segment: what the figures show

Amneal Pharmaceuticals brought in $3.02B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 8.0% from $2.79B in fiscal 2024. Affordable Medicines was the largest at $1.75B (57.8%), ahead of Avkare at $744.73M (24.7%) and Specialty at $528.51M (17.5%).

Compared with fiscal 2024, Specialty grew fastest, up 18.6% to $528.51M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $2.21B to $3.02B, a compound annual growth rate of 10.9%. Affordable Medicines' share of the total fell from 64.7% to 57.8%.

Annual history

Amneal Pharmaceuticals Revenue by Product & Service

Years FY 2019–2022
Lines 9
FY 2022 Total $2.20B

Subtotal Dosage Forms was Amneal Pharmaceuticals’s largest product and service line in fiscal 2022, bringing in $1.42B of $2.20B (65%).

Amneal Pharmaceuticals revenue by product and service, fiscal 2019 to 2022
Product and Service FY 2019 FY 2020 FY 2021 FY 2022
Subtotal Dosage Forms — — — $1.42B
Other Dosage Forms — — — $209.41M
Injectable — — — $188.94M
Auto-Injector — — — $140.56M
Transdermal — — — $119.29M
Oral Liquid — — — $108.41M
License Agreement — — — $8.02M
Biosimilar — — — $3.24M
International — — — $1.47M
Total $1.60B $1.99B $2.09B $2.20B
Totals include 18 discontinued lines from earlier reporting.

Amneal Pharmaceuticals revenue by product and service: what the figures show

Amneal Pharmaceuticals brought in $2.20B from its nine product and service lines in fiscal 2022, the year ended December 31, 2022. Amneal Pharmaceuticals regrouped these lines after fiscal 2021, so the total does not compare directly with that year's $2.09B. Subtotal Dosage Forms was the largest at $1.42B (64.6%), ahead of Other Dosage Forms at $209.41M (9.5%) and Injectable at $188.94M (8.6%). The other six lines brought in $380.99M combined.

Amneal Pharmaceuticals began breaking out Subtotal Dosage Forms in fiscal 2022, Other Dosage Forms in fiscal 2022, Injectable in fiscal 2022 and Auto-Injector in fiscal 2022. Amneal Pharmaceuticals stopped reporting Central Nervous System ($658.31M in fiscal 2021), Hormonal / Allergy ($495.47M in fiscal 2021), Hormonal/Allergy ($410.21M in fiscal 2020) and 15 others as separate lines.

Annual history

Amneal Pharmaceuticals Revenue by Geography

Years FY 2017
Lines 2
FY 2017 Total $1.02B

Us was Amneal Pharmaceuticals’s largest region in fiscal 2017, bringing in $946.60M of $1.02B (93%).

Amneal Pharmaceuticals revenue by geography, fiscal 2017 to 2017
Geography FY 2017
Us $946.60M
International $74.54M
Total $1.02B

Amneal Pharmaceuticals revenue by geography: what the figures show

Amneal Pharmaceuticals brought in $1.02B from its two regions in fiscal 2017, the year ended December 31, 2017. Us was the largest at $946.60M (92.7%), ahead of International at $74.54M (7.3%).

Questions

Amneal Pharmaceuticals Revenue Breakdown FAQ

How does Amneal Pharmaceuticals make money?

Amneal Pharmaceuticals (AMRX) reports its revenue by segment, by product and service and by geography. In fiscal 2025, Affordable Medicines was its largest segment, bringing in $1.75B (57.8% of the total), followed by Avkare at $744.73M (24.7%).

What is Amneal Pharmaceuticals' largest segment?

Affordable Medicines was Amneal Pharmaceuticals' largest segment in fiscal 2025, bringing in $1.75B, or 57.8% of the $3.02B total across its three segments.

What is Amneal Pharmaceuticals' largest product and service line?

Subtotal Dosage Forms was Amneal Pharmaceuticals' largest product and service line in fiscal 2022, bringing in $1.42B, or 64.6% of the $2.20B total across its nine product and service lines.

What is Amneal Pharmaceuticals' largest region?

Us was Amneal Pharmaceuticals' largest region in fiscal 2017, bringing in $946.60M, or 92.7% of the $1.02B total across its two regions.

Which Amneal Pharmaceuticals segment is growing the fastest?

Among Amneal Pharmaceuticals' segments that make up at least 2% of revenue, Specialty grew fastest in fiscal 2025, up 18.6% from $445.75M to $528.51M.

Where does this revenue breakdown data come from?

Every figure comes from Amneal Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Amneal Pharmaceuticals gives it, and years follow its fiscal calendar.

How far back does Amneal Pharmaceuticals' revenue breakdown go?

Amneal Pharmaceuticals' revenue by segment goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.